Ascletis, 3-V Biosciences ink strategic license agreement for NASH drug

China |  News | 0 Comment | 14 Feb, 2019

Ascletis Pharma through its subsidiary, and 3-V Biosciences have entered into an exclusive license agreement for 3-V Biosciences' FASN (fatty acid synthase) inhibitor TVB-2640 (Ascletis cod...Read more

3SBio and Verseau team up for Immuno-Oncology Therapies

China |  News | 0 Comment | 13 Feb, 2019

3SBio and Verseau Therapeutics have announced a partnership agreement focused on the development and commercialization of novel monoclonal antibodies in the field of immuno-oncology for a b...Read more

WuXi Biologics enters into commercial manufacturing partnership with Amicus

China |  News | 0 Comment | 13 Feb, 2019

WuXi Biologics, a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Amicus Therapeut...Read more

Samsung Bioepis, C-Bridge Capital to develop next-gen biosimilars

China |  News | 0 Comment | 12 Feb, 2019

Samsung Bioepis Co., Ltd. has announced its expansion in mainland China through a licensing agreement with C-Bridge Capital. The agreement covers multiple biosimilar candidates from Samsung...Read more

Female contraceptive market set to be worth $8.7bn by 2027

China |  News | 0 Comment | 11 Feb, 2019

Contraceptive market sales were estimated to be $6.3bn across the 8MM (US, France, Germany, Italy, Spain, UK, Japan and China) in 2017, which is expected to grow to $8.2bn in 2027, at ...Read more

Lunar New Year focuses on traditional chinese medicine for cancer treatment

China |  Opinion | 0 Comment | 09 Feb, 2019

The Lunar New Year welcomes a focus on the wellbeing of the entire body leading to renewed discussions about the benefits of traditional Chinese medicine (TCM).   The popularity of TC...Read more

CStone, IMPACT Therapeutics’ anti-tumor therapy gets IND filing acceptance

China |  News | 0 Comment | 08 Feb, 2019

CStone Pharmaceutical and IMPACT Therapeutics, Inc. have jointly announced that an Investigational New Drug (IND) filing has been accepted by the National Medical Products Administration (N...Read more

Invitrocue signs technology development agreement with SIBCB

China |  News | 0 Comment | 08 Feb, 2019

Invitrocue, a leading healthcare bio-analytic solutions provider, has announced the signing of a new technology development agreement with the Shanghai Institute of Biochemistry and Cell Bi...Read more

Glenmark Pharma signs an agreement with Grandpharma

China |  News | 0 Comment | 07 Feb, 2019

Glenmark Pharmaceuticals Ltd. (Glenmark) has announced that its Swiss subsidiary, Glenmark Specialty S.A., has entered into an exclusive licensing agreement with Grandpharma (China) Co. Ltd...Read more

EdiGene raises $10M in Series pre-B

China |  News | 0 Comment | 06 Feb, 2019

EdiGene Inc., headquartered in Beijing, with operational subsidiaries in Guangzhou, China and Cambridge, USA and which develops genome editing technologies into novel therapeutics for a bro...Read more

Reaction Biology Corporation buys ProQinase GmbH

China |  News | 0 Comment | 05 Feb, 2019

Reaction Biology Corporation ("RBC") and ChinaEquity Group ("CEG") have announced the conclusion of a stock exchange transaction through which RBC has acquired all the shares of ProQinase G...Read more

Accuray, CIRC to sell Radiation Oncology Systems in China

China |  News | 0 Comment | 05 Feb, 2019

Accuray Asia Limited, a subsidiary of Accuray Incorporated, and CNNC High Energy Equipment (Tianjin) Co., Ltd, a subsidiary of China Isotope and Radiation Corporation have announced the for...Read more

CARsgen Therapeutics receives IND clearance for GPC3-CAR-T Cells from NMPA

China |  News | 0 Comment | 04 Feb, 2019

CARsgen Therapeutics, a clinical-stage company committed to developing Chimeric Antigen Receptor T cell therapies for cancer has announced that one of its leading drug candidates, humanized...Read more

I-Mab, BCT to work on Arginine Depletion Therapy and Biomarker Study

China |  News | 0 Comment | 04 Feb, 2019

I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune disease...Read more

GeneQuantum Healthcare, MITRO Biotech to develop Radionuclide Conjugates

China |  News | 0 Comment | 04 Feb, 2019

GeneQuantum Healthcare of Suzhou and MITRO Biotech of Nanjing recently signed the "Strategic Cooperation Agreement on Next Generation Radionuclide Conjugates Development" in Nanji...Read more

I-Mab gets USFDA IND approval for its proprietary TJC4

China |  News | 0 Comment | 29 Jan, 2019

I-Mab Biopharma (I-Mab), a China-based clinical-stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune disease...Read more

Ping An Good Doctor develops new offline service scenario

China |  News | 0 Comment | 29 Jan, 2019

China's leading one-stop healthcare ecosystem platform Ping An Health Medical Technology Company Limited has announced that it has stationed a "One-minute Clinic" at the Nanjing Siqiao Expr...Read more

BioDuro partners with Advent International

China |  News | 0 Comment | 28 Jan, 2019

BioDuro, a leading global life sciences contract research and development organization, and Advent International, one of the largest and most experienced global private equity investor...Read more